Search
Paclitaxel Treatment Options in New York
A collection of 750 research studies where Paclitaxel is the interventional treatment. These studies are located in the New York, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
481 - 492 of 750
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Completed
The purpose of this study is to study a new treatment for HER2-positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2019
Locations: Memorial Sloan-Kettering Cancer Commack, Commack, New York +2 locations
Conditions: HER2-Positive Early Stage Breast Cancer
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
Terminated
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2019
Locations: Not set, Rochester, New York
Conditions: Hemodialysis Graft Dysfunction
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
Completed
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Breast Cancer
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Completed
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab.
The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Not set, Rochester, New York
Conditions: Metastatic Breast Cancer
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Terminated
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: Rosewell Park Cancer Institute Elm & Carlton Carlton Building, Buffalo, New York +3 locations
Conditions: Breast Neoplasms, Neoplasm Metastasis
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
Completed
Phase III Metastatic Pancreatic Cancer
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
11/07/2019
Locations: New York Oncology Hematology PC, Albany, New York +3 locations
Conditions: Metastatic Pancreatic Cancer
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
Completed
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Gender:
ALL
Ages:
All
Trial Updated:
10/30/2019
Locations: Arena Oncology Associates, Lake Success, New York
Conditions: Pancreatic Cancer
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
Completed
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/21/2019
Locations: Cornell University Weill Medical College, New York, New York
Conditions: Metastatic Pancreas Adenocarcinoma
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
Completed
The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2019
Locations: Mary Imogene Bassett Hospital, Cooperstown, New York
Conditions: Non-Small Cell Lung Carcinoma
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
Completed
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2019
Locations: ImClone Investigational Site, New York, New York
Conditions: Gastric Cancer
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
Completed
The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2019
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York
Conditions: Squamous Non Small Cell Lung Cancer
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Terminated
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Part 2 dose, safety and efficacy of MLN1117 (TAK-117) in combination with docetaxel, paclitaxel, investigational TAK-659 or investigational alisertib in adult participants with advanced and metastatic gastric or gastroesophageal adenocarcinoma. The study consists of a dose escalation phase (Part 1) and a dose expansion phase (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/19/2019
Locations: Not set, Lake Success, New York +1 locations
Conditions: Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma
481 - 492 of 750